Literature DB >> 36053470

The role of lactoferrin in atherosclerosis.

Cailong Chen1,2, Menglan Lu2, Zheng Zhang3, Liqiang Qin2.   

Abstract

Atherosclerosis (AS) is a common pathological basis for many cardiovascular diseases (CVDs) and result in high mortality and immense health and economic burdens worldwide. Early prevention, diagnosis, and treatment are promising approaches for stemming the development and progression of AS. Lactoferrin (Lf) is an iron-binding glycoprotein belonging to the transferrin family. It is widely found in body fluids such as digestive tract fluids, tears, and milk. Lf possesses anti-inflammatory, antibacterial, immunoregulatory, antioxidant and many other physiological functions. The serum Lf level is reportedly associated with the risk of AS and AS-related CVDs. Lf administration is closely involved in several mechanisms, including cholesterol metabolism, foam cell formation, ICAM-1 expression, homocysteine and leptin levels, anti-inflammatory and antioxidant function. Moreover, Lf has also been applied in the sythesis of magnetic resonance imaging (MRI) contrast agents to detect AS. Lf plays an important role in AS and may therefore be used in its diagnosis and treatment. Thus, this article aims to review the association between Lf and the risk of AS and AS-related CVDs, the mechanisms of Lf administration on AS, and its potential application in AS diagnosis.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular disease; Cholesterol metabolism; Lactoferrin

Year:  2022        PMID: 36053470     DOI: 10.1007/s10534-022-00441-1

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   3.378


  52 in total

1.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 2.  Bile Acid Metabolism in Liver Pathobiology.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Gene Expr       Date:  2018-01-11

3.  Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk.

Authors:  Fabio Angeli; Enrica Angeli; Giuseppe Ambrosio; Giovanni Mazzotta; Gianpaolo Reboldi; Paolo Verdecchia
Journal:  Obstet Gynecol       Date:  2010-04       Impact factor: 7.661

4.  Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex.

Authors:  S Baveye; E Elass; D G Fernig; C Blanquart; J Mazurier; D Legrand
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 5.  Lactoferrin as a natural immune modulator.

Authors:  Jeffrey K Actor; Shen-An Hwang; Marian L Kruzel
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 6.  Potential of anti-inflammatory agents for treatment of atherosclerosis.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Andrey V Grechko; Veronika A Myasoedova; Alexander N Orekhov
Journal:  Exp Mol Pathol       Date:  2018-01-31       Impact factor: 3.362

Review 7.  Lipoproteins, platelets and atherothrombosis.

Authors:  Lina Badimón; Gemma Vilahur; Teresa Padró
Journal:  Rev Esp Cardiol       Date:  2009-10       Impact factor: 4.753

8.  Correlation Between Arteriosclerosis and Periodontal Condition Assessed by Lactoferrin and α1-Antitrypsin Levels in Gingival Crevicular Fluid.

Authors:  Shuji Hayashi; Hirotsugu Yamada; Makoto Fukui; Hiro-o Ito; Masataka Sata
Journal:  Int Heart J       Date:  2015-11-09       Impact factor: 1.862

Review 9.  Immunity, atherosclerosis and cardiovascular disease.

Authors:  Johan Frostegård
Journal:  BMC Med       Date:  2013-05-01       Impact factor: 8.775

10.  Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

Authors:  E Hailman; H S Lichenstein; M M Wurfel; D S Miller; D A Johnson; M Kelley; L A Busse; M M Zukowski; S D Wright
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.